|
|
Notice: Manufacturer of Controlled Substances; Notice of Application
Federal Register: May 2, 2008 (Volume 73, Number 86)
Page 24313
Agency: DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 3, 2008, Abbott
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson
Road, Whippany, New Jersey 07981, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to manufacture bulk product and dosage units for
distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR Sec.
1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 1, 2008.
Dated: April 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-9696 Filed 5-1-08; 8:45 am]
BILLING CODE 4410-09-P
|